Back to User profile » Dr Smith
Paper published by Dr Smith:
Review
![Noteworthy comment: Asthma is currently affecting about 235 million people, and is the most common chronic disease in children. It is now well appreciated that asthma is not a simple disease. Reclassifying asthma with identification of sub-phenotypes has great impacts on choosing appropriate therapeutic approaches for improved treatment outcomes. It suggests that proper target should be chosen for individualized therapy. Accordingly, careful patient profiling and selection for clinical trials are extremely important. Moreover, many times, surrogate markers have to be used in clinical practice. This manuscript provided an excellent instruction of how to wisely choose appropriate biomarker(s) for patient classification and proper target(s) for improved therapy.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Lebrikizumab in the personalized management of asthma
Thomson NC, Patel M, Smith AD
Biologics: Targets and Therapy 2012, 6:329-335
Published Date: 14 September 2012
Back to User profile » Dr Smith
Thomson NC, Patel M, Smith AD
Biologics: Targets and Therapy 2012, 6:329-335
Published Date: 14 September 2012